Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus INCASSIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus INCASSIA.
CU-7 vs INCASSIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
INCASSIA (bleomycin) is an antineoplastic antibiotic that causes DNA strand breaks through free radical generation, inhibiting DNA synthesis and cell division.
50 mg orally once daily
1.5 mg orally once daily, administered with or without food.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing, though dose adjustment is required in renal impairment (CrCl <30 mL/min).
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose, with biliary/fecal elimination contributing about 20-30%. Less than 10% is metabolized.
Category C
Category C
Contraceptive
Contraceptive